Delivery Order SPE2DB24D2105-SPE2DB24FAPPY

Award Date 7/9/24
Potential Completion Date 7/10/24
Potential Value $9.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $9,651.30 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml medication, with a period of performance through April 3, 2025. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml. The contract has a firm fixed price of $3,759.96 and a completion date of February 25, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as the primary vehicle for providing a comprehensive range of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, with a ceiling value of $11,322.20 and a completion date of December 6, 2024. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a larger Indefinite...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml medication. The award, valued at $15,871.71, has a completion date of January 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This is a $2,337.33 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml to the DLA, which is responsible for the Medical Supply Chain. The contract has an ultimate completion date of May 30, 2024. While the original solicitation was not provided, this delivery order appears to be part of a larger...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $8,770.10 firm-fixed-price contract is for the supply of the pharmaceutical product Ozempic 1 mg/dose (4 mg/3 ml) 3 ml. This order was placed under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC enables DLA to efficiently...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml. The $32,883.73 firm fixed-price contract has an ultimate completion date of July 5, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml. The $23,898.70 fixed-price contract has a period of performance running through February 5, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as the primary vehicle for providing a...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml. The contract has a firm fixed price of $8,980.08 and a period of performance through January 15, 2025. There is no set-aside designation for this award. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
This is a $7,005 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml medication, with a performance period through December 3, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
  • SPE2DB24D2105
    Indefinite Delivery Contract
  • SPE2DB24D2105-SPE2DB24FAPPY
    Delivery Order

This is a delivery order (contract award) issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml. The contract has a firm fixed price of $9,396.70 and a completion date of July 10, 2024. This delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have any set-aside designation, indicating it was competitively awarded.

Generated 5/17/25, 10:06 AM